Compare iShares International Treasury Bond ETF (IGOV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Tango Therapeutics Inc. — how do they compare? iShares International Treasury Bond ETF trades at $39.67 (market cap $1.31B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 2.9× iShares International Treasury Bond ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Tango Therapeutics Inc. for 0 Days on average.
| IGOV | TNGX | |
|---|---|---|
Market Cap | $1.31B | $3.74B |
Volume | 69,817 | 3,438,781 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $32.90 |
52-Week Low | $39.58 | $7.50 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.79, up 0.53% with mixed technical signals showing bearish moving averages but bullish oscillators. The stock faces resistance at $40-$42 while finding support near $39. Financial ratios remain unavailable, requiring deeper fundamental analysis to assess valuation and profitability metrics.
The stock's outlook remains uncertain with technical indicators conflicting and limited fundamental data available. Rising bond yields create macroeconomic headwinds for equities, though inverse Treasury ETF opportunities mentioned in recent news could signal defensive positioning. Investors need updated financial disclosures to properly evaluate investment merit.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
